en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
3/2024
vol. 99
 
Poleć ten artykuł:
Udostępnij:
streszczenie artykułu:
Opis przypadku

Eight-week treatment with sofosbuvir/velpatasvir may be effective in curing hepatitis C in children

Maria Pokorska-Śpiewak
1, 2
,
Anna Dobrzeniecka
2
,
Magdalena Marczyńska
1, 2

  1. Department of Children’s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland
  2. Department of Paediatric Infectious Diseases, Regional Hospital of Infectious Diseases, Warsaw, Poland
Pediatr Pol 2024; 99 (3): 266-269
Data publikacji online: 2024/09/20
Pełna treść artykułu Pobierz cytowanie
 
Metryki PlumX:


Sofosbuvir/velpatasvir (SOF/VEL) is a safe and effective regimen used for the treatment of chronic hepatitis C. The standard treatment duration is 12 weeks. There are no data available to support the shortened treatment. We aimed to present a case of an 11-year-old boy treated with a generic SOF/VEL for 8 weeks. The patient was admitted to our department 12 weeks after the end of treatment to establish the efficacy of the therapy (sustained virological response, SVR12). Laboratory testing revealed aminotransferases and bilirubin levels within the normal ranges, there were no abnormalities in the abdomen ultrasound, and transient elastography did not reveal any liver fibrosis. Hepatitis C virus (HCV) RNA tested with reverse-transcription polymerase chain reaction method was undetectable. The patient achieved SVR12. We conclude that shortening treatment with SOF/VEL to 8 weeks may be effective for HCV elimination in children. The possibility of treatment shortening should be confirmed in further studies on larger groups of paediatric patients.